Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 134

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy

Mehrotra, N, Gupta, M, Kovar, A, Meibohm, B·2007·International Journal of Impotence Research
DOI 10.1038/sj.ijir.3901522
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.ijir.3901522

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Meibohm B, Derendorf H . Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997; 35: 401–413.
  2. Holford NH, Sheiner LB . Kinetics of pharmacologic response. Pharmacol Ther 1982; 16: 143–166. · DOI
  3. Meibohm B, Evans WE . Clinical pharmacokinetics and pharmacodynamics. In: Helms R, Quan D, Herfindal ET, Gourley DR (eds.) Textbook of Therapeutics: Drug and Disease Management, 8th edn. Lippincott Williams & Wilkins: Baltimore, 2006 pp 1–30.
  4. Mandagere AK, Thompson TN, Hwang KK . Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 2002; 45: 304–311. · DOI
  5. Derendorf H, Meibohm B . Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999; 16: 176–185. · DOI
  6. Slaughter RL, Edwards DJ . Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619–624. · DOI
  7. Evans WE, Relling MV . Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491. · DOI
  8. Guengerich FP . Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 2004; 36: 159–197. · DOI
  9. Eichelbaum M, Ingelman-Sundberg M, Evans WE . Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119–137. · DOI · Paper page
  10. Ingelman-Sundberg M . Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 89–104. · DOI
  11. Klaassen CD, Watkins III JB . Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev 1984; 36: 1–67.
  12. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M . Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002; 41: 751–790. · DOI
  13. Curtis G, Colburn W, Heath G, Lenehan T, Kotshwar T . Faster drug development: using early drug development to understand your compound. Appl Clin Trials 2000; 9: 52–55.
  14. Gupta M, Kovar A, Meibohm B . The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005; 45: 987–1003. · DOI · Paper page
  15. Rosen RC, Kostis JB . Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92: 9M–18M. · DOI
  16. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19: 32–39. · DOI
  17. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181–188. · DOI
  18. Eardley I, Cartledge J . Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002; 56: 300–304. · DOI
  19. Gresser U, Gleiter CH . Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil – review of the literature. Eur J Med Res 2002; 7: 435–446.
  20. Sussman DO . Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc 2004; 104: S11–S15.
  21. Muirhead GJ, Rance DJ, Walker DK, Wastall P . Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 2002; 53 (Suppl 1): 13S–20S. · DOI
  22. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297–310. · DOI
  23. CDER/FDA. NDA 021368 Cialis (Tadalafil) Tablets-Clinical Pharmacology/Biopharmaceutics Review. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Silver Spring, MD, 2003.
  24. Nichols DJ, Muirhead GJ, Harness JA . Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53 (Suppl 1): 5S–12S. · DOI
  25. Brock GB . Tadalafil: a new agent for erectile dysfunction. Can J Urol 2003; 10 (Suppl 1): 17–22.
  26. Ormrod D, Easthope SE, Figgitt DP . Vardenafil. Drugs Aging 2002; 19: 217–227. · DOI
  27. Curran M, Keating G . Tadalafil. Drugs 2003; 63: 2203–2212; discussion 2213–2204. · DOI · Paper page
  28. Cheitlin MD, Hutter Jr AM, Brindis RG, Ganz P, Kaul S, Russell Jr RO et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273–282. · DOI · Paper page
  29. CDER/FDA. NDA 021400 Levitra (Vardenafil Hydrochloride) Tablets – Clinical Pharmacology/Biopharmaceutics Review. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Silver Spring, MD, 2003.
  30. Milligan PA, Marshall SF, Karlsson MO . A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 2002; 53 (Suppl 1): 45S–52S. · DOI
  31. Wilkinson GR, Shand DG . Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377–390. · DOI
  32. CDER/FDA. NDA 020895 Viagra (Sildenafil citrate) Tablets – Clinical Pharmacology/Biopharmaceutics Review. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Silver Spring, MD, 1998.
  33. Staab A, Tillmann C, Forgue ST, Mackie A, Allerheiligen SR, Rapado J et al. Population dose–response model for tadalafil in the treatment of male erectile dysfunction. Pharm Res 2004; 21: 1463–1470. · DOI
  34. Bischoff E . Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004; 16 (Suppl 1): S11–S14. · DOI
  35. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–290. · DOI
  36. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM . Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164–2171. · DOI · Paper page
  37. Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE . Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005; 39: 1286–1295. · DOI
  38. Hatzimouratidis K, Hatzichristou DG . A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005; 65: 1621–1650. · DOI
  39. Webb DJ, Freestone S, Allen MJ, Muirhead GJ . Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C–28C. · DOI · Paper page
  40. Cotreau MM, von Moltke LL, Greenblatt DJ . The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44: 33–60. · DOI

Cited by

See all 134

Metadata

Authors
Mehrotra, N., Gupta, M., Kovar, A., & Meibohm, B.
Venue
International Journal of Impotence Research
Publisher
Springer Science and Business Media LLC
Published
2006-09-21
Volume
19
Issue
3
Pages
253-264
ISSN
  • 0955-9930
  • 1476-5489
DOI
10.1038/sj.ijir.3901522
Cited by
134
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.